Source: International Congress 2019 – Clinical challenges in respiratory infection
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
N. Hamao (Kyoto, Japan), I. Ito (Kyoto, Japan), S. Konishi (Kyoto, Japan), N. Tanabe (Kyoto, Japan), I. Oi (Kyoto, Japan), T. Hirai (Kyoto, Japan). Frequency of side effects in antibiotic treatment for pneumonia. 4552

Member's Comments

No comment yet.

Related content which might interest you: Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Barriers to an early switch from intravenous to oral antibiotic therapy in hospitalised patients with CAP Source: Eur Respir J 2013; 41: 123-130 Year: 2013 Influence of antibiotic pre-treatment on inflammatory markers in community-acquired pneumonia Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Active monitoring of adverse drug reactions to the use of beta-lactam antibiotics in the treatment of community-acquired pneumonia Source: Virtual Congress 2020 – Cardiovascular and pulmonary complications of respiratory infections Year: 2020 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Colistin as a first choice antibiotic for the initial empiric antimicrobial therapy of ventilator-associated pneumonia Source: Eur Respir J 2007; 30: 1234-1235 Year: 2007 Appropriateness and delay to initiate therapy in ventilator-associated pneumonia Source: Eur Respir J 2006; 27: 158-164 Year: 2006 Determinants of prescription and choice of empirical therapy for hospital-acquired and ventilator-associated pneumonia Source: Eur Respir J 2011; 37: 1332-1339 Year: 2011 Frequency of antibiotic resistance and outcomes in severe community acquired pneumonia due to Streptococcus pneumoniae Source: Annual Congress 2009 - Aetiology and treatment of community-acquired pneumonia Year: 2009 Antibiotic usage analysis for community-acquired pneumonia (CAP) treatment Source: Annual Congress 2009 - Pulmonary infections Year: 2009 Influence of adherence to clinical guidelines in empiric antibiotics choice on outcomes of community-acquired pneumonia in hospitalized Belarussian patients Source: Eur Respir J 2005; 26: Suppl. 49, 637s Year: 2005 Treatment failure in pneumonia: impact of antibiotic treatment and cost analysis Source: Eur Respir J 2012; 39: 611-618 Year: 2012 Pharmacokinetic optimisation of β-lactams for the treatment of ventilator-associated pneumonia Source: Eur Respir Rev 2007; 16: 45-49 Year: 2007 Impact of macrolide therapy on mortality in severe sepsis caused by pneumonia Source: Eur Respir J 2009; 33: 521 Year: 2009 Timing of antibiotic administration and outcomes for patients with community-acquired pneumonia (CAP). NAC-CV Study Source: Eur Respir J 2006; 28: Suppl. 50, 349s Year: 2006 Effectiveness of the empirical administration of antibiotics in community acquired pneumonia (CAP) Source: Annual Congress 2007 - Antibiotic treatment in community-acquired pneumonia Year: 2007 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006